131 related articles for article (PubMed ID: 25159163)
1. CCR1 and CCR2 antagonists.
Zimmermann HW; Sterzer V; Sahin H
Curr Top Med Chem; 2014; 14(13):1539-52. PubMed ID: 25159163
[TBL] [Abstract][Full Text] [Related]
2. Pyrrolone Derivatives as Intracellular Allosteric Modulators for Chemokine Receptors: Selective and Dual-Targeting Inhibitors of CC Chemokine Receptors 1 and 2.
Ortiz Zacarías NV; van Veldhoven JPD; Portner L; van Spronsen E; Ullo S; Veenhuizen M; van der Velden WJC; Zweemer AJM; Kreekel RM; Oenema K; Lenselink EB; Heitman LH; IJzerman AP
J Med Chem; 2018 Oct; 61(20):9146-9161. PubMed ID: 30256641
[TBL] [Abstract][Full Text] [Related]
3. Chemokine receptor antagonists: Part 1.
Pease JE; Horuk R
Expert Opin Ther Pat; 2009 Jan; 19(1):39-58. PubMed ID: 19441897
[TBL] [Abstract][Full Text] [Related]
4. Chapter 12. The use of receptor homology modeling to facilitate the design of selective chemokine receptor antagonists.
Carter PH; Tebben AJ
Methods Enzymol; 2009; 461():249-79. PubMed ID: 19480923
[TBL] [Abstract][Full Text] [Related]
5. Identification of a sulfonamide series of CCR2 antagonists.
Peace S; Philp J; Brooks C; Piercy V; Moores K; Smethurst C; Watson S; Gaines S; Zippoli M; Mookherjee C; Ife R
Bioorg Med Chem Lett; 2010 Jul; 20(13):3961-4. PubMed ID: 20627722
[TBL] [Abstract][Full Text] [Related]
6. CXCR2 receptor antagonists: a medicinal chemistry perspective.
Dwyer MP; Yu Y
Curr Top Med Chem; 2014; 14(13):1590-605. PubMed ID: 25159161
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of beta-chemokines MCP-1 and RANTES and their receptors CCR1, CCR2, CCR5 in acute rejection and chronic allograft nephropathy of human renal allografts.
Rüster M; Sperschneider H; Fünfstück R; Stein G; Gröne HJ
Clin Nephrol; 2004 Jan; 61(1):30-9. PubMed ID: 14964455
[TBL] [Abstract][Full Text] [Related]
8. Differential involvement of Galpha16 in CC chemokine-induced stimulation of phospholipase Cbeta, ERK, and chemotaxis.
Tian Y; Lee MM; Yung LY; Allen RA; Slocombe PM; Twomey BM; Wong YH
Cell Signal; 2008 Jun; 20(6):1179-89. PubMed ID: 18406577
[TBL] [Abstract][Full Text] [Related]
9. The multiple faces of CCL13 in immunity and inflammation.
Mendez-Enriquez E; García-Zepeda EA
Inflammopharmacology; 2013 Dec; 21(6):397-406. PubMed ID: 23846739
[TBL] [Abstract][Full Text] [Related]
10. Cross-desensitization of CCR1, but not CCR2, following activation of the formyl peptide receptor FPR1.
Bednar F; Song C; Bardi G; Cornwell W; Rogers TJ
J Immunol; 2014 Jun; 192(11):5305-13. PubMed ID: 24778447
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of 9-cis retinoic acid on expression of CC chemokine receptors in human monocytes.
Kim IS; Kim YS; Jang SW; Sung HJ; Han KH; Na DS; Ko J
Biochem Pharmacol; 2004 Aug; 68(4):611-20. PubMed ID: 15276068
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of chemokine receptor antagonists for liver disease.
Sahin H; Berres ML; Wasmuth HE
Expert Rev Clin Pharmacol; 2011 Jul; 4(4):503-13. PubMed ID: 22114859
[TBL] [Abstract][Full Text] [Related]
13. CCR1 and CCR2 Coexpression on Monocytes Is Nonredundant and Delineates a Distinct Monocyte Subpopulation.
Medina-Ruiz L; Bartolini R; Mathie H; Halawa HA; Cunningham M; Graham GJ
J Immunol; 2024 Jul; 213(2):214-225. PubMed ID: 38829123
[TBL] [Abstract][Full Text] [Related]
14. Multiple binding sites for small-molecule antagonists at the CC chemokine receptor 2.
Zweemer AJ; Nederpelt I; Vrieling H; Hafith S; Doornbos ML; de Vries H; Abt J; Gross R; Stamos D; Saunders J; Smit MJ; Ijzerman AP; Heitman LH
Mol Pharmacol; 2013 Oct; 84(4):551-61. PubMed ID: 23877010
[TBL] [Abstract][Full Text] [Related]
15. CCR1- and CCR5-mediated inactivation of leukocytes by a nonglycosaminoglycan (non-GAG)-binding variant of n-nonanoyl-CCL14 (NNY-CCL14).
Gupta S; Rieder S; Richter R; Schulz-Maronde S; Manns J; Escher SE; Heitland A; Mack M; Forssmann WG; Elsner J; Forssmann U
J Leukoc Biol; 2010 Aug; 88(2):383-92. PubMed ID: 20483925
[TBL] [Abstract][Full Text] [Related]
16. Expression of the chemokine receptors CCR1 and CCR2B is up-regulated in peripheral blood B cells upon EBV infection and in established lymphoblastoid cell lines.
Kholodnyuk I; Rudevica Z; Leonciks A; Ehlin-Henriksson B; Kashuba E
Virology; 2017 Dec; 512():1-7. PubMed ID: 28892735
[TBL] [Abstract][Full Text] [Related]
17. Temporal expression and cellular origin of CC chemokine receptors CCR1, CCR2 and CCR5 in the central nervous system: insight into mechanisms of MOG-induced EAE.
Eltayeb S; Berg AL; Lassmann H; Wallström E; Nilsson M; Olsson T; Ericsson-Dahlstrand A; Sunnemark D
J Neuroinflammation; 2007 May; 4():14. PubMed ID: 17484785
[TBL] [Abstract][Full Text] [Related]
18. Role of the chemokine receptors CCR1, CCR2 and CCR4 in the pathogenesis of experimental dengue infection in mice.
Guabiraba R; Marques RE; Besnard AG; Fagundes CT; Souza DG; Ryffel B; Teixeira MM
PLoS One; 2010 Dec; 5(12):e15680. PubMed ID: 21206747
[TBL] [Abstract][Full Text] [Related]
19. Ly6C
Schloss MJ; Hilby M; Nitz K; Guillamat Prats R; Ferraro B; Leoni G; Soehnlein O; Kessler T; He W; Luckow B; Horckmans M; Weber C; Duchene J; Steffens S
Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1640-1645. PubMed ID: 28663258
[TBL] [Abstract][Full Text] [Related]
20. New therapeutics that modulate chemokine networks.
Schwarz MK; Wells TN
Nat Rev Drug Discov; 2002 May; 1(5):347-58. PubMed ID: 12120410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
